Skip to main content

Table 4 Tumour characteristics of HCC cases according to IL-10 polymorphism

From: Association of IL-10 and TNF-α polymorphisms with risk and aggressiveness of hepatocellular carcinoma in patients with HCV-related cirrhosis

  Total, n = 73 Genotype Test of significance
  TT/AA CT/CA CC/CC
Portal vein
 Thrombosed 10 10 (34.5) 0 (0.0) 0 (0.0) MC
P < 0.001*
 Patent 63 19 (65.5) 21 (100.0) 23 (100.0)
Spleen
 Splenectomy 2 0 (0.0) 2 (9.5) 0 (0.0) MC
P = 0.154
 Mild 26 7 (24.1) 11 (52.4) 8 (34.8)
 Moderate 39 19 (65.5) 8 (38.1) 12 (52.2)
 Marked 6 2 (6.9) 2 (9.5) 2 (8.7)
Ascites
 Negative 62 20 (69.0) 19 (90.5) 23 (100.0) MC
P = 0.006*
 Positive 11 9 (31.0) 2 (9.5) 0 (0.0)
Lymph node
 Negative 64 23 (79.3) 21 (100.0) 20 (87.0) MC
P = 0.089
 Positive 9 6 (20.7) 0 (0.0) 3 (13.0)
BCLC
 A 11 0 (0.0) 7 (33.3) 4 (17.4) MC
P < 0.001*
 B 24 3 (10.3) 7 (33.3) 14 (60.9)
 C 24 13 (44.8) 7 (33.3) 4 (17.4)
 D 14 13 (44.8) 0 (0.0) 1 (4.3)
Site of lesion
 Right lobe 25 10 (34.5) 6 (28.6) 9 (39.1) MC
P = 0.929
 Left lobe 12 5 (17.2) 3 (14.3) 4 (17.4)
 Multifocal 36 14 (48.3) 12 (57.1) 10 (43.5)
AGI
 A 22 2 (6.9) 8 (38.1) 12 (52.2) MC
P < 0.001*
 B 23 6 (20.7) 9 (42.9) 8 (34.8)
 C 28 21 (72.4) 4 (19.0) 3 (13.0)
  1. * means statistically significant